Programs Designed to Address Unmet Needs in Infectious Diseases
Spero Therapeutics’ antibiotic pipeline is focused on areas for which the unmet medical need is greatest, the biological rationale for treatment is clear, and for which there are few approved therapies, or where the standard of care is suboptimal.
Our pipeline of anti-infective agents is one of the most unique in the industry and consists of four complementary product candidates, including:
- SPR994 Oral Gram-Negative Program is a first in class oral carbapenem that has demonstrated potent in vitro and in vivo activity against a wide variety of Gram-negative bacterial infections, including those harboring drug-resistant extended-spectrum beta-lactamases (ESBLs).
- SPR741 IV Potentiator Platform is our technology designed to treat serious and life-threatening multi-drug resistant Gram-negative pathogens, such as Enterobacteriaceae, with combination therapies.
The following table illustrates our product candidates, their status, our current estimated development timeline and anticipated milestones.
Product Candidate Pipeline and Anticipated Milestones
*Our ability to progress SPR994 to a pivotal Phase 3 clinical trial is subject to a pre-Phase 3 meeting with the FDA to confirm that no additional clinical trials or preclinical studies are required prior to initiating a Phase 3 clinical trial.
**Our ability to progress SPR741 to a Phase 2 clinical trial depends on obtaining results from our Phase 1 and Phase 1b clinical trials that are satisfactory to the FDA.
This chart contains forward-looking statements. Our planned development activities and anticipated milestones are based on our current assumptions, estimates and plans, which may change.